Stock Ratings / Health Care / WOK / financials

NVNO (50) SNOA (44) AMIX (37) INBS (38) ⌘ Pro Terminal →

WORK Medical Technology Group LTD (Class A) (WOK) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is WORK Medical Technology Group LTD (Class A) (WOK)?

In FY 2025 (10-K), WOK converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $4.9M in free cash flow (0.1% FCF margin).

$1.10 -4.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

WORK Medical Technology Group LTD (Class A) (WOK) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $4.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.09 (-0.97%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WOK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY WOK SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($4.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$1.53-28.8% Next Q

Q2 (-2Q)

Grade C$1.09+1.8% Next Q

Q3 (-1Q)

Grade C$1.11-0.9% Next Q

Current

Grade D+$1.10-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WOK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WOK currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.71) and Max Pain ($1.16) forces dealer call-delta covering toward $87,780.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WOK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “WOK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How WOK Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$4.9M (0.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	0%	-$1.1M	$4.9M	15%
FY 2024	$4.00B	52%	0%	-$3.5M	-$11.5M	15%
FY 2023	$4.00B	52%	0%	$112.0K	$2.2M	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WOK)

✓Walkthrough of WOK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WOK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.09%▲ RESISTANCE BREAKOUT

2026-10-30O $1.07H $1.10L $1.00C $1.10VOL 60.7K

RES: $0.91SUP: $0.88SMA50: $1.71SMA200: $63.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WOK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WOK Butterfly Map → + Track WOK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WOK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WOK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WOK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WOK)

Health Care Rank #298 of 1016 ⚔️ NVNO vs WOK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WOK vs. NVNO, SNOA, AMIX, INBS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, WORK Medical Technology Group LTD (Class A) (WOK) ranks #298 by composite RQD confidence (54/100, grade D+) and #950 by equity capitalization ($4.9M). Within this direct 5-issuer industry benchmark cohort, WOK leads on earnings valuation at N/A trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WOK ACTIVE WORK Medical Technology Group LTD (Class A)	D+	54/100	—	—	—	-4.35%	$4.9M	Benchmark Subject
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-wok →
SNOA Sonoma Pharmaceuticals Inc.	D	44/100	—	38.0%	-35.0%	+5.26%	$5.7M	/snoa-vs-wok →
AMIX Autonomix Medical Inc.	D-	37/100	—	—	-35.0%	-5.12%	$4.0M	/amix-vs-wok →
INBS Intelligent Bio Solutions Inc.	D-	38/100	—	40.8%	-35.0%	+9.58%	$6.1M	/inbs-vs-wok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001929783

In its most recent audited fiscal period (FY2025, filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.1M, operating cash flow of $6.2M, and free cash flow of $4.9M (+142.9% YoY). On the balance sheet, WOK closed FY2025 with $33.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	-$1.1M	$6.2M	$4.9M	$33.2M	—
FY2024 (FY)	2024-09-30	$0	-$3.5M	-$2.2M	-$11.5M	—	—
FY2023 (FY)	2023-09-30	$0	$112.0K	$2.2M	$2.2M	—	—

3. WOK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.10 (-4.35% 1D, market cap $4.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WOK ranks #298 in composite RQD confidence.

How does WOK compare to NVNO and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $4.9M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, WOK leads on earnings multiple (N/A) while NVNO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WOK?

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $0 in revenue, -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WOK trading relative to its 50-day, 200-day, and 52-week technical levels?

WOK last traded at $1.10 (-4.35% on volume of 12,674 shares), positioning the stock -35.67% below its 50-day simple moving average ($1.71) and -98.26% below its 200-day simple moving average ($63.31). Across its 52-week range of $1.00 to $83,600.00, WOK sits at the 0.0% percentile with a 14-day RSI of 27.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.24).

WOK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is WORK Medical Technology Group LTD (Class A) (WOK)?

In FY 2025 (10-K), WOK converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $4.9M in free cash flow (0.1% FCF margin).

Direct Sub-Reports: WOK RQD Cockpit WOK 12M Forecast WOK Earnings & Move WOK Dividends & DRIP WOK Insiders & 13F WOK Whale Options WOK Profit Sankey WOK News & Why